Pemafibrate Ameliorates Steatotic Liver Disease Regardless of Endothelial Dysfunction in Mice

Endothelial dysfunction contributes to the progression of metabolic-dysfunction-associated steatotic liver disease (MASLD). Pemafibrate has been shown to ameliorate MASLD in basic and clinical studies, but it is unclear whether it is also effective in the status of endothelial dysfunction. An MASLD...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Antioxidants
المؤلفون الرئيسيون:	Tomoyo Hara, Hiroki Yamagami, Ryoko Uemoto, Akiko Sekine, Yousuke Kaneko, Kohsuke Miyataka, Taiki Hori, Mayuko Ichimura-Shimizu, Masafumi Funamoto, Takeshi Harada, Tomoyuki Yuasa, Shingen Nakamura, Itsuro Endo, Ken-ichi Matsuoka, Yutaka Kawano, Koichi Tsuneyama, Yasumasa Ikeda, Ken-ichi Aihara
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	MDPI AG 2025-07-01
الموضوعات:	MASLD pemafibrate eNOS endothelial dysfunction oxidative stress NADPH oxidase
الوصول للمادة أونلاين:	https://www.mdpi.com/2076-3921/14/7/891